Vecuronium

Vecuronium
Systematic (IUPAC) name
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17S)- 17-acetyloxy-10,13-dimethyl-16-(1-methyl-3,4, 5,6-tetrahydro-2H-pyridin-1-yl)-2-(1-piperidyl)- 2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro- 1H-cyclopenta[a]phenanthren-3-yl] acetate
Identifiers
CAS number	50700-72-6
ATC code	M03AC03
PubChem	39765
Chemical data
Formula	C34H57N2O4+
Mol. mass	557.827 g/mol
Pharmacokinetic data
Bioavailability	100% (IV)
Metabolism	liver 30%
Half life	51–80 minutes (longer with renal failure)
Excretion	Fecal (40-75%) and renal (30% as unchanged drug and metabolites)
Therapeutic considerations
Pregnancy cat.	Additional recommended knowledge Don't let static charges disrupt your weighing accuracy Daily Visual Balance Check Correct Test Weight Handling Guide: 12 Practical Tips C(US)
Legal status
Routes	Intravenous

Vecuronium bromide (trade name Norcuron) is a muscle relaxant in the category of non depolarising neuromuscular blocking agents. Vecuronium bromide is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Although vecuronium bromide is often thought of as a muscle relaxant, it may be more accurate to classify it as a paralyzing agent.

Clinical pharmacology

Vecuronium operates by competing for the cholinergic receptors at the motor end plate thereby exerting its muscle relaxing properties which are used adjunctively to general anesthesia. Under balanced anesthesia, the time to recovery to 25% of control (clinical duration) is approximately 25 to 40 minutes after injection and recovery is usually 95% complete approximately 45 to 65 minutes after injection of intubating dose. The neuromuscular blocking action of vecuronium is slightly enhanced in the presence of potent inhalation anesthetics. If vecuronium is first administered more than 5 minutes after the start of the inhalation of enflurane, isoflurane, or halothane, or when steady state has been achieved, the intubating dose of vecuronium may be decreased by approximately 15%.

Vecuronium is normally given at 0.08–0.1 mg/kg intravenously and its maintenance dose is usually between 0.02–0.03 mg/kg, but as with all other neuromuscular blocking agents, the doses need to be tailored for each individual patient.

It is an aminosteroid.

See also

• Pancuronium